Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

计划入组 73 人 · 首次发布于 2025 年 4 月 18 日

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

计划入组 650 人 · 首次发布于 2024 年 6 月 7 日

Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

计划入组 27 人 · 首次发布于 2013 年 5 月 23 日

GSK-2302032A

EGFR inhibitors (non-small cell lung cancer)

GFPT2 inhibitors (non-small-cell lung cancer)

ADDARIO LUNG CANCER MEDICAL INSTITUTE

United States

European Lung Cancer Working Party

Belgium

Summit Therapeutics Inc.

United States

Bicycle Therapeutics Delays Zelenectide Pevedotin Regulatory Update to Q1 2026 Amid Multi-Agency Consultations

Bicycle Therapeutics' Zelenectide Pevedotin Shows Promise in NECTIN4-Amplified Cancers

iTeos Therapeutics Announces Strategic Priorities for 2025, Anticipating Multiple Data Readouts